Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00097604
Status:
COMPLETED
Last Update Posted:
2010-07-29
First Post:
2004-11-24
Brief Title:
Effects of Valerian on Sleep in Healthy Older Adults
Sponsor:
University of Washington
Organization:
University of Washington
Study Overview
Official Title:
Valerian for Sleep Disturbance in Healthy Older Adults
Status:
COMPLETED
Status Verified Date:
2009-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to examine the way valerian an herbal sleep agent is absorbed and distributed in the body This study will also compare the effects of valerian after 1 week versus after 2 weeks
Detailed Description:
Sleep disturbances are common among the elderly and may increase the risk for depression and early mortality Use of over-the-counter sleep aids may disrupt sleep patterns and have serious side effects Herbal medicines have the potential to improve sleep quality Evidence suggests that valerian may improve sleep with a low rate of side effects but its efficacy has not been thoroughly examined in the elderly This study will determine the effectiveness and pharmacokinetics PK of valerian in older adults who experience disturbances in their sleep
This study will last 8 weeks At the sleep clinic participants will be randomly assigned to receive either valerian or placebo on the first night of study enrollment Participants will have an intravenous IV line inserted into their arms and multiple blood draws will be taken during their sleep for PK studies The next day participants will be sent home for a drug wash-out period and will return after 1 week for a 3-night stay at the clinic on Nights 8 9 and 10 On Night 8 participants will adjust to their surroundings and begin a sleep log to describe the quality of their sleep they will continue to note observations on their sleep in the sleep log for the duration of the study Recordings of each participants sleeping and breathing patterns will be taken on Nights 8 and 9 to screen for sleep disorders On Night 10 participants will again be randomly assigned to receive either valerian or placebo After Night 10 participants will be sent home and asked to continue taking their assigned intervention nightly for 11 nights Participants will be asked to continue their sleep logs and begin a symptom log describing insomnia symptoms After 11 nights participants will return for another 3-night stay at the clinic on Nights 22 23 and 24 participants will receive either valerian or placebo Participants will then be sent home for a 12-day drug wash-out period participants will return to the clinic for Nights 37 and 38 Night 37 will be an adaptation night on Night 38 participants will be given the intervention they were not yet assigned on Night 24 After Night 38 participants will be asked to go home and continue their second treatment for 11 nights participants will come back to the sleep clinic for another 3-night stay on Nights 50 51 and 52 for observation and PK studies After Night 52 participants will be sent home and asked to continue their sleep and symptoms logs for two more nights then mail the logs to study researchers for analysis
During this study participants will be asked to keep logs of the quality of their sleep and of the insomnia symptoms they may be experiencing In addition to the logs post-sleep interviews will be used to assess the quality of participants sleep and the number of awakenings Participants heart and breathing rates and leg movements will be measured during their stays at the sleep clinic Participants will also have an activity monitoring device attached to either their wrist or waist for most of the study
This study will last 8 weeks At the sleep clinic participants will be randomly assigned to receive either valerian or placebo on the first night of study enrollment Participants will have an intravenous IV line inserted into their arms and multiple blood draws will be taken during their sleep for PK studies The next day participants will be sent home for a drug wash-out period and will return after 1 week for a 3-night stay at the clinic on Nights 8 9 and 10 On Night 8 participants will adjust to their surroundings and begin a sleep log to describe the quality of their sleep they will continue to note observations on their sleep in the sleep log for the duration of the study Recordings of each participants sleeping and breathing patterns will be taken on Nights 8 and 9 to screen for sleep disorders On Night 10 participants will again be randomly assigned to receive either valerian or placebo After Night 10 participants will be sent home and asked to continue taking their assigned intervention nightly for 11 nights Participants will be asked to continue their sleep logs and begin a symptom log describing insomnia symptoms After 11 nights participants will return for another 3-night stay at the clinic on Nights 22 23 and 24 participants will receive either valerian or placebo Participants will then be sent home for a 12-day drug wash-out period participants will return to the clinic for Nights 37 and 38 Night 37 will be an adaptation night on Night 38 participants will be given the intervention they were not yet assigned on Night 24 After Night 38 participants will be asked to go home and continue their second treatment for 11 nights participants will come back to the sleep clinic for another 3-night stay on Nights 50 51 and 52 for observation and PK studies After Night 52 participants will be sent home and asked to continue their sleep and symptoms logs for two more nights then mail the logs to study researchers for analysis
During this study participants will be asked to keep logs of the quality of their sleep and of the insomnia symptoms they may be experiencing In addition to the logs post-sleep interviews will be used to assess the quality of participants sleep and the number of awakenings Participants heart and breathing rates and leg movements will be measured during their stays at the sleep clinic Participants will also have an activity monitoring device attached to either their wrist or waist for most of the study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 04-2201-D 01 | OTHER | University of Washington Human Subjects Division | httpsreporternihgovquickSearchR21AT002108-01 |
| R21AT002108-01 | NIH | None | None |